NFC
KYNB

Northeast Financial Consultants’s Kyntra Bio KYNB Stock Holding History

Northeast Financial Consultants’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,188
Closed -$17K – 302
2025
Q1 		$17K Hold
2,188
– – ﹤0.01% 276
2024
Q4 		$29K Hold
2,188
– – ﹤0.01% 285
2024
Q3 		$21.8K Hold
2,188
– – ﹤0.01% 291
2024
Q2 		$48.8K Buy
+2,188
New +$67.6K ﹤0.01% 267
2022
Q2 		– Sell
-2,188
Closed -$657K – 356
2022
Q1 		$657K Buy
+2,188
New +$763K 0.04% 194
2019
Q4 		– Sell
-402
Closed -$372K – 321
2019
Q3 		$372K Buy
+402
New +$442K 0.04% 206

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northeast Financial Consultants's KYNB Position: Q2 2025 in Review

Northeast Financial Consultants sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 2,188 shares — an estimated $17K sold.

Northeast Financial Consultants first reported a position in KYNB in Q3 2019 and held it in 6 quarters. The position peaked at $657K in Q1 2022. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

  • Northeast Financial Consultants reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
  • Northeast Financial Consultants sold 2,188 Kyntra Bio shares in Q2 2025, an estimated $17K.
  • Northeast Financial Consultants first reported a position in Kyntra Bio in Q3 2019 and held it in 6 quarters.
  • Northeast Financial Consultants's Kyntra Bio position peaked at $657K in Q1 2022.
  • 30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.